Bibliography
- LIEBERMAN JA: Understanding the mechanism of action of atypical antipsychotic drugs. Br. J. Psychiatry (1993) 163 (Supp1.2):7–18.
- BARIK S, DE BEAUREPAIRE R: Evidence for a functional role of the dopamine D3 receptor in the cerebellum. Brain Res. (1996) 737:347–350.
- SOKOLOFF P, GOROS B, MARTRES M-P, BOUTHENET M-L, SCHWARTZ J-C: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature (1990) 347:146–151.
- SEEMAN P, GUAN H-C, VAN TOL HH: Dopamine D4 receptors elevated in schizophrenia. Nature (1993) 365:441–445.
- REYNOLDS DA: The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs (1996) 51(1):7–11.
- OHUOHA DC, HYDE TM, KLEINMAN JE: The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology (1993) 112:S5–S12.
- ROTH BL, CRAIGO SC, CHOUDARY MS et aL: Binding of typical and atypical antipsychotic agents to 5-HT6 and 5-HT7 receptors. J. PharmacoL Exp. Ther. (1994) 268(3):1403–1410.
- REAVILL C: The therapeutic potential of 5-HT6 receptor antagonists. Curr. Opin. Invest. Drugs (2001) 2:104–109.
- REAVILL C, KETTLE A, HOLLAND V RILEY G, BLACKBURN TP: Attenuation of haloperidol-induced catalepsy by a 5-HT2, antagonist. Br. J. PharmacoL (1999) 126:572–574.
- BUSATTO GF, KERWIN RW: Perspectiveson the role of serotonergic mechanisms in the pharmacology of schizophrenia. PsychopharmacoL (1997) 11(1):3–12.
- BRISTOW LJ, O'CONNOR D, WATTS R, DUXON MS, HUTSON PH: Evidence for accelerated desensitization of 5-HT2, receptors following combined treatment with fluoxetine and the 5-HTIA receptor antagonist, WAY 100,635, in the rat. Neuropharmacology (2000) 39(7):1222–1236.
- MACDONALD GJ, BRANCH Cl, HADLEY MS et aL: Design and synthesis of trans-3-(2-(44(3-(3-(5-methyl-1,2,4-oxadiazoly1))phenyl)carboxamido)cyclohexy Dethyl)-7-methyl-sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist. J. Med. Chem. (2003) 46(23):4952–4964.
- MELTZER HY, MATSUBARA S, LEE JC:Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin-2 pK, values. J. PharmacoL Exp. Ther. (1989) 251(1):238–246.
Websites
- http://www.iddb3.com/iddb3/iddb3_2/ reports.display?id58048aemplateDrug&i _query_id57806538ci_clear_trailY IDdb3 drug report for SKF–103829.